News

News 2008 :

• Nov 05 2008 Publication in NATURE Magazine of an article describing the design of a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis.
  
  
• Oct 23 2008 Cellectis and Genomic Vision receive 10 million euros of funding from Oséo-ISI to develop a revolutionary treatment for HIV and herpes.
  
  
• Sep 25 2008 Cellectis S.A. announces its financial results for the 1^st half of 2008: Net income of €1.3m with 100% increase in expenses and 200% in sales.
  
  
• Sep 16 2008 The French Muscular Dystrophy Association (AFM) and Cellectis launch a genome surgery program for curing genetic diseases.
  
  
• July 03 2008 Cellectis and Regeneron sign an agreement over the use of homologous recombination technology.
  
  
• June 30 2008 Biotechnology company Cellectis S.A. announces the inception of two subsidiaries: Cellectis BioResearch to develop and market research kits and Cellectis Genome Surgery to develop therapeutics.
  
  
• May 9 2008 Cellectis sues Shionogi for infringement of its Patents concerning Homologous Recombination Technology.
  
  
• Apr 22 2008 Cellectis announces the publication of a paper entitled "Computer design of obligate heterodimer meganucleases allows efficient cutting of custom DNA sequences" in Nucleic Acids Research.
  
  
• Apr 10 2008 Cellectis S.A. announces participation in the SmallCap Event On April 21^st and 22^nd in Paris, 'hotel Hilton Suffren' in Paris.
  
  
• Apr 08 2008 Cellectis S.A. announces its financial results for 2007: operating expenses grow (+27%) in parallel with sales (+22%).
  
  
• Mar 13 2008 Cellectis sues Precision BioSciences for Infringement of its patents concerning Meganuclease technology.
  
  
• Feb 27 2008 The biotechnology company Cellectis S.A. announces a turnover of around €425k for the fourth quarter of 2007.
  
  
• Feb 21 2008 Cellectis announces positive outcome in IP battle.
  
  
• Jan 16 2008 Cellectis S.A. Annonce son Calendrier Financier et de Relations Investisseurs pour 2008, ainsi que la mise à disposition d'informations dédiées sur son site web.
  
  

News 2007 :

• Dec 10 2007 Two significant nominations for Cellectis: Professor Alain Fischer joins the Scientific Advisory Board and Alain Godard joins the Board of Directors.
  
  
• Dec 06 2007 Cellectis announces the publication of a key article in the Journal of Biological Chemistry.
  
  
• Nov 15 2007 Cellectis announces delivery of a meganuclease targeting the RAG1 gene (responsible for a severe immunodeficiency) to Professor Luigi Notarangelo's research group at the Children's Hospital Boston (USA).
  
  
• Nov 13 2007 La société de biotechnologie Cellectis S.A. annonce un chiffre d'affaires de 161k€ au troisième trimestre 2007.
  
  
• Oct 15 2007 Cellectis grants TransGenic a non-exclusive license to its homologous recombination technology.
  
  
• Oct 08 2007 Laboratoires Servier and Cellectis sign an agreement in the field of cell engineering.
  
  
• Sep 25 2007 Cellectis' Financials for First Semester 2007.
  
  
• Sep 15 2007 Cellectis announces the presentation of results demonstrating the correction of an XP mutation in a patient's cell line by homologous gene targeting at the first French-German meeting on DNA repair, damage signaling and carcinogenesis in Toulouse.
  
  
• Sep 14 2007 Cellectis annonce la livraison d'une méganucléase ciblant le gène IL2RG responsable d'une immunodéficience sévère liée au chromosome X (enfants-bulles X-SCID) à l'Equipe du Professeur Alain Fisher, Hôpital Necker (INSERM U768).
  
  
• Sep 11 2007 Cellectis S.A. announces participation in the MidCap Event.
  
  
• July 26 2007 Cellectis announces the delivery of two meganucleases targeting the p53 gene in the framework of the NETSENSOR European program.
  
  
• June 26 2007 Cellectis announces the publication of a paper entitled " Engineered I-CreI Derivatives Cleaving Sequences from the Human XPC Gene can Induce Highly Efficient Gene Correction in Mammalian Cells" in the Journal of Molecular Biology.
  
  
• June 18 2007 Election of Professor Richard C. Mulligan to Cellectis' Board of Directors.
  
  
• June 11 2007 Cellectis S.A. wins a patent battle in the field of targeted recombination and gene correction.
  
  
• June 04 2007 The Institut Pasteur and Cellectis announce the grant of a key European patent covering the use of homologous recombination in eukaryotes.
  
  
• May 30 2007 Cellectis S.A.'s first combined Annual and Special Shareholders General Meeting, May 30, 2007.
  
  
• May 28 2007 Cellectis reaches key milestone in collaboration with Bayer Cropscience on uses of Meganuclease technology in plants.
  
  
• May 23 2007 Cellectis will begin continuous trading on Alternext of Euronext Paris on May 24^th 2007.
  
  
• May 22 2007 INFORMATION CONCERNING CELLECTIS S.A.'S FIRST COMBINED ANNUAL AND SPECIAL SHAREHOLDERS GENERAL MEETING - Meeting is due to be held on May 30 2007.
  
  
• May 10 2007 Cellectis announces the publication of a paper entitled "The C-terminal loop of the homing endonuclease I-CreI is essential for site recognition, DNA binding and cleavage" in the journal Nucleic Acids Research.
  
  
• May 04 2007 Cellectis grants GlaxoSmithKline a non-exclusive sub-license for its homologous recombination technology.
  
  
• May 03 2007 Cellectis S.A. announces its attendance at two high-profile conventions: The BIO International Convention, Boston, May 6^th-9^th 2007 and BioEquity Europe , Glasgow, May 21^st-22^nd 2007.
  
  
• Apr 17 2007 Cellectis S.A. announces its financial results for the fiscal year ending Dec 31 2006.
  
  
• Apr 12 2007 April the 13^rd, 2007, Cellectis will host for the second year, the next GDR 2825 workshop on "Novel approaches on Directed Protein Evolution", at his Romainville headquarters (Paris region).
  
  
• Apr 03 2007 Celonic and Cellectis announce a commercial license agreement following key milestone in meganuclease-mediated cell line engineering for biomanufacturing.
  
  
• Apr 02 2007 Cellectis S.A. Announces its 2007 Financial and Investor Relations Calendar.
  
  
• Mar 30 2007 Cellectis S.A., the Alternext-listed innovative company, receives a €1.4 million grant from OSEO Innovation (ANVAR).
  
  
• Mar 19 2007 Cellectis S.A. announces the publication of a Current Gene Therapy article on Meganucleases and its Perspectives for Gene Therapy.
  
  
• Mar 05 2007 Cellectis S.A. announces the full exercise of the greenshoe in the context of its initial public offering on the Alternext market of Euronext Paris.
  
  
• Feb 06 2007 Cellectis S.A. announces the success of its initial public offering on the Alternext market of Euronext Paris.
  
  
• Jan 23 2007 Cellectis S.A. announces the launch of its initial public offering on the Alternext market of Euronext Paris.
  
  
• Jan 08 2007 Cellectis S.A. announces the publication of a Journal Nucleic Acids Research (NAR) article on artificial homing endonuclease.
  
  

News 2006 :

• Dec 26 2006 Cellectis S.A. announces the registration of its Document de Base with the AMF in the context of the Company's contemplated initial public offering on the Alternext market of Euronext Paris.
  
  
• Oct 18 2006 Cellectis is distinguished with the Ernst & Young Entrepreneur Award as the "High Prospective Company" of Year 2006.
  
  
• Oct 02 2006 Cellectis Appoints Marc Le Bozec As Chief Financial Officer.
  
  
• Jul 11 2006 Cellectis has been granted a worldwide License to Lexicon Genetics' Isogenic DNA Technology.
  
  
• Jul 11 2006 Lexicon Genetics Granted Exclusive License to Cellectis' Homologous Recombination Technology.
  
  
• Jun 30 2006 Cellectis and Bayer CropScience enter into a collaboration to use Meganuclease technology in plants.
  
  
• May 23 2006 June the 2^nd 2006, Cellectis will host the next GDR 2825 workshop on "Novel approaches on Directed Protein Evolution", at his Romainville headquarters (Paris region).
  
  
• Apr 19 2006 Cellectis and Genentech have entered into a worldwide, non-exclusive license agreement under patent families relating to a process for the specific replacement or insertion of a gene in the receiver genome by homologous recombination for in vitro and in vivo manipulations of genetic material.
  
  
• Mar 14 2006 Cellectis announces publication of data demonstrating ability of meganucleases to induce efficient in toto recombination in mouse liver.
  
  
• Feb 21 2006 Cellectis SA and Celonic GmbH enter in collaboration and license agreement for mammalian cell lines engineering for bio-production purposes.
  
  
• Jan 03 2006 Cellectis and BASF Plant Science sign a License under the Meganuclease technology for marker genes excision in crops.
  
  

News 2005 :

• Dec 20 2005 Cellectis S.A. Announces an Agreement with Shire Pharmaceuticals in the field of gene activated proteins
  
  
• Dec 13 2005 Cellectis signs Worldwide Non-Exclusive License agreement with AstraZeneca covering the use of the Homologous Recombination
  
  
• Nov 23 2005 Cellectis SA reports method for the selection of novel engineered meganucleases in Nucleic Acids Research
  
  
• Nov 21 2005 Cellectis SA reports the Engineering of large numbers of Novel Highly Specific Homing Endonucleases, in the Journal of Molecular Biology
  
  
• Nov 03 2005 Cellectis distinguished with the Research Company of Year 2005 Award.
  
  
• Oct 18 2005 Cellectis is awarded the "Best Pharma Partnering" Trophy 2005 by Pharma Industry Association
  
  
• Sep 21 2005 Cellectis announces Research Collaboration and License Agreement with Biogen Idec to engineer a novel customized Meganuclease Recombination System.
  
  
• Jul 31 2005 Cellectis SA reports in Biotechniques on factors affecting meganuclease-induced recombination of direct repeats in mammalian cells.
  
  
• Jul 12 2005 Cellectis S.A. and Ozgene Pty Ltd. Enter into a License Agreement.
  
  
• Jun 29 2005 Cellectis S.A. Announces a License Agreement with Xenogen Biosciences Corporation.
  
  
• Jun 14 2005 Cellectis S.A. wins patent battle in the field of targeted recombination and gene correction.
  
  
• May 31 2005 Cellectis S.A. and Celliance^TM, a Serologicals Company, enter in collaboration for mammalian cell lines engineering for production purposes.
  
  

News 2004 :

• Dec 16 2004 Cellectis is distinguished with the Entrepreneur of the Year 2004 award.
  
  
• Nov 23 2004 Bankinvest is awarded the Investor's Trophy at BIORIF 2004 for its investment in Cellectis SA.
  
  
• Nov 22 2004 Cellectis S.A. Grants Lexicon Genetics a Technology Sublicense.
  
  
• May 26 2004 Cellectis S.A., with the intermediation of Ascenion GmbH, has entered into a multi-tiered license agreement with four German Academic Research Centers, for its patents family covering certain uses of Homologous Recombination.
  
  
• May 13 2004 Cellectis S.A. and Murinus GmbH enter into a License agreement for the use of the Homologous Recombination in generating mouse models.
  
  
• Mar 1 2004 Cellectis SA has moved to a new facility at Aventis' Biocitech Park, in Romainville, Paris area.
  
  
• Feb 25 2004 Cellectis SA extends its Technology Agreement with BASF Plant Science GmbH for marker genes excision in crops.
  
  
• Feb 11 2004 Cellectis announces a License agreement with Regeneron Pharmaceuticals relating to the use of the Homologous Recombination in Velocigene© Platform.
  
  
• Jan 06 2004 Cellectis SA and Diversa enter into a License Agreement for microorganisms improvement.
  

News 2003 :

• Nov 18 2003 Cellectis SA and Fermentas enter into a License Agreement.
  
  
• Jun 3 2003 Cellectis SA announces publication in Nucleic Acids Research of the generation of a novel hybrid meganuclease.
  
  
• May 19 2003 Cellectis SA and BASF Plant Science GmbH enter into Technology Agreement.
  
  
• Apr 16 2003 Cellectis grants Nucleis a non-exclusive commercial license under the patent family covering the use of the homologous recombination in mice.
  
  
• Apr 9 2003 Cellectis and Limagrain Group announce an agreement.
  
  
• Apr 1 2003 Cellectis grants Deltagen a Worldwide Non-Exclusive License under the Patent Family covering the use of the Homologous Recombination in Rodents.
  
  
• Mar 26 2003 Two major patents on homologous recombination issued in the United States.
  
  
• Mar 6 2003 Pioneer to Assess Cellectis Technology for Use in Trait Development.
  
  

News 2002 :

• Sep 19 2002 Cellectis and Artemis Pharmaceuticals sign a license agreement.
  
  
• Jun 25 2002 Cellectis SA announces the completion of its second financing round.
  
  

News 2001 :

• Oct 23 2001 Cellectis and genOway sign a license agreement.
  
  
• Aug 30 2001 Cellectis and Zentaris sign a license agreement.
  
  
• Mar 15 2001 Cellectis conducts expertise for CNES on Mars sample return.
  
  

News 2000 :

• Dec 8 2000: Cellectis grows and moves to the Biotop Pasteur incubator.
  
  
• Sep 21 2000: Official press release from CELLECTIS and Pasteur Institute: CELLECTIS wins competition
  
  
• Sep 20 2000: CELLECTIS SA is awarded a special prize as the first Biotech Company in nationwide competition.